Active Ingredient History
Tetraethylenepentamine (TEPA) is a low-molecular-weight linear polyamine exerting metal-chelating properties. TEPA is widely used in industrial applications. The principal hazards that arise in working with TEPA are those associated with similar organic amines; namely, a corrosive action on skin and eyes. TEPA biological activity was attributed to its effect on cellular Cu levels as (a) treatment with TEPA resulted in reduction of cellular Cu, and (b) excess of Cu reversed TEPA's activity and accelerated differentiation. TEPA was shown to attenuate the differentiation of ex vivo cultured hematopoietic cells resulting in preferential expansion of early progenitors. A phase I/II trial was performed to test the feasibility and safety of transplantation of CD133+ cord blood (CB) hematopoietic progenitors cultured in media containing stem cell factor, FLT-3 ligand, interleukin-6, thrombopoietin and TEPA. Transplanting a population of CD133+ CB cells which were expanded ex vivo for 21 days using SCF, FLT3, IL-6, TPO and the copper chelator TEPA (StemEx) was feasible. The expanded cells were well tolerated, with no infusion-related adverse events observed. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arterial Occlusive Diseases (Phase 3)
Atherosclerosis (Phase 3)
Breast Neoplasms (Phase 2)
Cardiovascular Diseases (Phase 3)
Carotid Artery Diseases (Phase 3)
Cerebrovascular Disorders (Phase 3)
Coronary Artery Disease (Phase 3)
Coronary Disease (Phase 3)
Drugs, Investigational (Phase 1)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Hematologic Neoplasms (Phase 2)
Hypercholesterolemia (Phase 4)
Hyperlipidemias (Phase 4)
Intracranial Arteriosclerosis (Phase 3)
Myocardial Ischemia (Phase 3)
Protoporphyria, Erythropoietic (Phase 2/Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
